Melanoma Market Analysis and Forecast to 2026-Global Comparison of Patient Population by Age, Sex, Stage at Diagnosis and Survival

Tue Nov 14, 2017 - 11:30am GMT+0000

Orbis Research has announced the addition of the “EpiCast Report: Melanoma-Epidemiology Forecast to 2026” to store by company, by country, and by application/type for the competitive landscape analysis.

Dallas, United States – November 14, 2017

Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of skin. Melanoma is considered an aggressive form of cancer; however, if caught early, it can be treated very successfully. Melanoma is one of the most common cancer types in the US, and is considered the national cancer of Australia. Melanoma risk factors include increasing age, sex, fair complexion, excessive ultraviolet (UV) light exposure, history of sunburn, having many (more than 50) moles, a personal history of cancer of the skin, a family history of melanoma, immunosuppression, and certain medical conditions including, but not limited to, xeroderma pigmentosum (XP) and atypical mole (dysplastic nevi) syndrome.

Browse the complete report @ http://www.orbisresearch.com/reports/index/epicast-report-melanoma-epidemiology-forecast-to-2026

In the 7MM, GlobalData epidemiologists forecast the diagnosed incident cases of melanoma to increase from 165,651 cases in 2016 to 206,717 cases in 2026, at an Annual Growth Rate (AGR) of 2.48%. The US will have the highest number of melanoma cases throughout the forecast period. The fiveyear diagnosed prevalent cases of melanoma in the 7MM are also expected to increase from 724,704 cases in 2016 to 909,265 cases in 2026 at an AGR of 2.55%.

GlobalData’s epidemiological forecast for the diagnosed incident and fiveyear diagnosed prevalent cases of Melanoma in the 7MM is supported by age and sexspecific incidence data drawn from national cancer registries. Additionally, the analysis is strengthened by the use of a consistent methodology across the 7MM for the diagnosed incident cases forecast, using regression techniques to evaluate trends, and is based on 10 years of countryspecific historical data points pertaining to the age and sexspecific diagnosed incidence of melanoma.

Get request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/518836

Scope
The Melanoma EpiCast Report provides an overview of the risk factors and global trends of melanoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Australia). It includes a 10year epidemiological forecast for the diagnosed incident cases and fiveyear diagnosed prevalent cases of melanoma segmented by age (beginning at 18 years and ending at 80 years and older), sex, and cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV).
The melanoma epidemiology report is written and developed by Masters and PhDlevel epidemiologists.
The EpiCast Report is indepth, high quality, transparent and marketdriven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Melanoma EpiCast report will allow you to
Develop business strategies by understanding the trends shaping and driving the global melanoma market.
Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for melanoma therapeutics in each of the markets covered.
Compare patient population potentials by age, sex, stage at diagnosis, and survival.

Get DISCOUNT on this report @ http://www.orbisresearch.com/contacts/discount/518836

List Of Tables:

1.1 List of Tables
Table 1: Risk Factors for Melanoma of the Skin 9
Table 2: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 19
Table 3: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, Select Years 2016-2026 22

1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 5
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Men and Women, Ages ≥18 Years, 2016 and 2026 6
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2006-2026 10
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2006-2026 11
Figure 5: 7MM, Sources Used and Not Used to Forecast Diagnosed Incident Cases of Melanoma, 2016 12
Figure 6: 7MM, Sources Used to Forecast Five-Year Diagnosed Prevalent Cases of Melanoma, 2016 13
Figure 7: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, 2016 14
Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of Melanoma, Men and Women, 2016 20
Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of Melanoma, Ages ≥18 Years, 2016 21
Figure 10: 7MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Men and Women, Ages ≥18 Years, 2016 23

About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Info:
Name: Hector Costello
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U.S.A.
Phone: +1 (214) 884-6817

LEAVE A REPLY